Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (7598)	10/30/1998 2:36:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Thanks fo the repost. Having a problem believing that this "news" is what moved stock. The information contained in the presentation has been available, IMO, for some time. In the patents and in other abstracts. As Rocketman says, the vast majority don't understand the importance of this, so why react to dull news? But admit market psychology is important and for all I know announcements that would have produced a yawn, two months ago, now stimulate buying. But just think, there probably is something else, generating interest. At any rate time will tell and if the stock moves on any other news, I will claim I was right! <g>

To: Bluegreen who wrote (7598)	10/30/1998 3:40:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

What else do we know about this meeting? Who else presented and from what companies? I think this meeting is of greater near term importance for XOMA than the LBP press release. How can we find out what was asked and answered? BTW sgonzalez deserves credit for seeing this first. Does not mean she agrees it is more important. FDA Advisory Committee: Safety of Biological Agents in Psoriasis 22-23, Bethesda, MD Marvin Garovoy, MD, Question and Answer

To: Bluegreen who wrote (7598)	10/30/1998 4:35:00 PM
From: aknahow	Respond to of 17367

Found this. Not much better than nothing. Suggestions as to availability of info from meetings? DERMATOLOGIC AND OPHTHALMIC DRUGS ADVISORY COMMITTEE DATE AND TIME: Oct. 21 and 22, 8 a.m. LOCATION: Holiday Inn, Walker Room, Two Montgomery Village Ave., Gaithersburg, MD. CONTACT: Tracy K. Riley or Angie Whitacre, Center for Drug Evaluation and Research, 301-827-7001. On Oct. 21, the committee will discuss products for the treatment of psoriasis>. On the morning of Oct. 22, the committee will discuss systemic immunomodulatory biological products intended for the treatment of <psoriasis. On the afternoon of Oct. 22, the committee will discuss products intended for the treatment of tinea capitis. 208.192.104.177